BillionToOne, Inc. (BLLN) Financial Statements
Industry: Medical Laboratories (Services)
In fiscal 2025, BillionToOne reported revenue of $305.1M. Net income was $7.5M (a 2.4% net margin), or $0.14 per diluted share. Gross margin was 68.3% and operating margin was 5.3%. Operating activities generated $24.6M of cash, leaving $15.7M of free cash flow. At fiscal year end, BillionToOne held $632.7M in total assets against $152.5M in total liabilities, including $496.0M of cash and equivalents.
Open the full interactive BillionToOne financials → Quarterly statements, key ratios, valuation history and price charts.
BillionToOne Key Stats
| Share Price | $94.44 |
|---|---|
| Market Cap | $5.14B |
| P/E Ratio | 674.6 |
| 52-Week Range | $64.03 – $149.97 |
| Shares Outstanding | 46.4 million (basic, 2026 Q2) |
BillionToOne Income Statement
| FY 2025 | |
|---|---|
| Revenue | $305.1M |
| Cost of Goods Sold | $96.7M |
| Gross Profit | $208.5M |
| Operating Income | $16.0M |
| Pre-Tax Income | $7.8M |
| Income Tax | $305,000 |
| Net Income | $7.5M |
| Diluted EPS | $0.14 |
BillionToOne Quarterly Results
| 2025 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|
| Revenue | $83.5M | $108.4M | $109.4M |
| Net Income | $5.7M | $18.0M | $8.1M |
| Diluted EPS | $0.10 | $0.34 | $0.15 |
BillionToOne Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $496.0M |
| Current Assets | $560.6M |
| Total Assets | $632.7M |
| Current Liabilities | $48.0M |
| Total Long-Term Debt | $57.2M |
| Total Liabilities | $152.5M |
| Shareholders' Equity | $480.1M |
BillionToOne Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | $24.6M |
| Cash From Investing | -$8.9M |
| Cash From Financing | $288.8M |
| Free Cash Flow | $15.7M |
Figures from BillionToOne's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full BillionToOne financials page for every line item.
BillionToOne Company Profile
| Ticker | BLLN |
|---|---|
| Exchange | Nasdaq |
| Industry | Medical Laboratories (Services) |
| Headquarters | Menlo Park, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, emerging growth company |
| SEC CIK | 0002070849 |
Frequently Asked Questions
What was BillionToOne's revenue in fiscal 2025?
BillionToOne (BLLN) reported revenue of $305.1M for fiscal 2025.
What was BillionToOne's net income in fiscal 2025?
BillionToOne reported net income of $7.5M for fiscal 2025.
What was BillionToOne's earnings per share (EPS) in fiscal 2025?
BillionToOne's diluted EPS was $0.14 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did BillionToOne generate in fiscal 2025?
BillionToOne generated $15.7M of free cash flow in fiscal 2025.
What was BillionToOne's revenue last quarter?
In its most recent reported quarter (2026 Q2), BillionToOne reported revenue of $109.4M.
How much debt does BillionToOne have?
BillionToOne reported $57.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of BillionToOne are outstanding?
BillionToOne reported a weighted average of 46.4 million basic shares outstanding in 2026 Q2.
What is BillionToOne's market cap?
Based on its latest closing price, BillionToOne (BLLN) has a market capitalization of about $5.14B.
When does BillionToOne's fiscal year end?
BillionToOne's fiscal year end, as registered with the SEC, is December 31.
Where is BillionToOne headquartered?
BillionToOne lists its business address in Menlo Park, California in its SEC filings.